NASDAQ:NTRA

Natera (NTRA) Stock Forecast, Price & News

$46.71

+1.74 (+3.87%)

(As of 02:22 PM ET)

Compare

Today's Range: $45.20
▼
$46.80
50-Day Range: $43.40
▼
$62.52
52-Week Range: $34.00
▼
$63.00

Volume: 635,246 shs
Average Volume: 1.20 million shs
Market Capitalization: $5.35 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $70.22

Natera MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 50.4% Upside
$70.22 Price Target
Short Interest: Bearish
6.13% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.92
Based on 2 Articles This Week
Insider Trading: Selling Shares
$1.96 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($4.03) to ($2.64) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

446th out of 963 stocks

Medical Laboratories Industry

13th out of 23 stocks

3.5

Analyst's Opinion

Consensus Rating
Natera has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $70.22, Natera has a forecasted upside of 50.4% from its current price of $46.69.
Amount of Analyst Coverage
Natera has only been the subject of 4 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.13% of the outstanding shares of Natera have been sold short.
Short Interest Ratio / Days to Cover
Natera has a short interest ratio ("days to cover") of 6.6.
Change versus previous month
Short interest in Natera has recently increased by 4.93%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Natera does not currently pay a dividend.
Dividend Growth
Natera does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NTRA.

2.2

News and Social Media Coverage

News Sentiment
Natera has a news sentiment score of 0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Natera this week, compared to 3 articles on an average week.
Search Interest
Only 9 people have searched for NTRA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
6 people have added Natera to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Natera insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,962,053.00 in company stock.
Percentage Held by Insiders
Only 9.42% of the stock of Natera is held by insiders.
Percentage Held by Institutions
92.59% of the stock of Natera is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Natera are expected to grow in the coming year, from ($4.03) to ($2.64) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Natera is -9.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Natera is -9.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Natera has a P/B Ratio of 6.46. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Natera (NASDAQ:NTRA) Stock

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company's products also comprise Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

NTRA Price History

30 days | 90 days | 365 days | Advanced Chart

NTRA Stock News Headlines

September 18, 2023 | finance.yahoo.com

Natera Announces Senior Leadership Appointments

September 14, 2023 | finance.yahoo.com

Unveiling Natera (NTRA)'s Value: Is It Really Priced Right? A Comprehensive Guide

September 27, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

September 14, 2023 | finance.yahoo.com

Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting

September 7, 2023 | msn.com

Natera down 3%, prices $250M follow-on offering

September 7, 2023 | markets.businessinsider.com

Natera Prices Follow-On Offering At $55/share, Totaling $250 Mln

September 7, 2023 | finance.yahoo.com

Natera Announces Pricing of $250 Million Follow-On Offering

September 6, 2023 | barrons.com

Natera Inc.

September 27, 2023 | Edge On The Street (Ad)

Is Gold Really Boring?

Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.

September 5, 2023 | finance.yahoo.com

Natera (NTRA) Reported Solid Quarterly Revenue Despite a Share Price Decline

September 2, 2023 | uk.finance.yahoo.com

Natera, Inc. (NTRA) stock price, news, quote & history – Yahoo Finance

August 23, 2023 | fool.com

Natera (NASDAQ: NTRA)

August 16, 2023 | finance.yahoo.com

Natera’s Prospera™ Lung Transplant Assessment Test Granted Medicare Coverage

August 15, 2023 | seekingalpha.com

Natera: Strong Growth Amidst Profitability Challenges

August 8, 2023 | msn.com

Morgan Stanley Maintains Natera (NTRA) Overweight Recommendation

August 8, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Natera

August 5, 2023 | finance.yahoo.com

Natera, Inc. (NASDAQ:NTRA) Q2 2023 Earnings Call Transcript

August 4, 2023 | seekingalpha.com

Natera, Inc. 2023 Q2 - Results - Earnings Call Presentation

August 3, 2023 | finance.yahoo.com

Natera Reports Second Quarter 2023 Financial Results

August 3, 2023 | finance.yahoo.com

Natera to Participate in Canaccord Genuity 43rd Annual Growth Conference

August 2, 2023 | benzinga.com

Natera Earnings Preview

July 31, 2023 | businesswire.com

Natera Files Patent Infringement Suit Against NeoGenomics

July 28, 2023 | markets.businessinsider.com

BTIG Sticks to Its Buy Rating for Natera (NTRA)

July 28, 2023 | finance.yahoo.com

Natera Announces Completion of Enrollment to the Randomized, Phase III ALTAIR Trial of Signatera™ in Colorectal Cancer

July 27, 2023 | finance.yahoo.com

Natera to Report its Second Quarter 2023 Results on August 3rd

July 21, 2023 | markets.businessinsider.com

What 7 Analyst Ratings Have To Say About Natera

July 18, 2023 | finance.yahoo.com

CareDx Applauds District Court Decision to Uphold Jury Verdict that Natera Falsely Advertised its Prospera Transplant Test

See More Headlines

Receive NTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter.

NTRA Company Calendar

Last Earnings: 8/03/2023
Today: 9/27/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NTRA
CUSIP: N/A
CIK: 1604821
Web: www.natera.com
Phone: (650) 249-9090
Fax: N/A
Employees: 3,018
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $70.22
High Stock Price Forecast: $80.00
Low Stock Price Forecast: $60.00
Forecasted Upside/Downside: +50.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.82)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-547,800,000.00
Net Margins: -54.97%
Pretax Margin: -54.92%
Return on Equity: -88.47%
Return on Assets: -41.19%

Debt

Debt-to-Equity Ratio: 0.47
Current Ratio: 3.85
Quick Ratio: 3.69

Sales & Book Value

Annual Sales: $931.05 million
Price / Sales: 5.74
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.23 per share
Price / Book: 6.45

Miscellaneous

Outstanding Shares: 114,602,000
Free Float: 103,806,000
Market Cap: $5.35 billion
Optionable: Optionable
Beta: 1.11

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Matthew Rabinowitz Ph.D. (Age 50)
Co-Founder & Exec. Chairman
Comp: $441.58k

Mr. Steven Leonard Chapman (Age 44)
CEO, Pres & Director
Comp: $1.15M

Mr. Michael B. Brophy M.B.A. (Age 43)
Chief Financial Officer
Comp: $611.35k

Mr. Daniel Rabinowitz L.L.M. (Age 54)
LL.M., Sec. & Chief Legal Officer
Comp: $566.03k

Mr. Jonathan Sheena M.Eng. (Age 50)
Co-Founder & Director

Ms. Olesya A. Anisimova CPA
Chief Accounting Officer

Mr. Rishi Kacker
Chief Technology Officer

Mr. Eric A. Evans
Chief Scientific Officer

Mr. Jerry Diffley
Chief Compliance & Privacy Officer

Mr. Phil Grinnell
VP of Sales

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NTRA Stock - Frequently Asked Questions

Should I buy or sell Natera stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NTRA shares.
View NTRA analyst ratings or view top-rated stocks.
What is Natera's stock price forecast for 2023?: 6 brokers have issued 12 month price targets for Natera's shares. Their NTRA share price forecasts range from $60.00 to $80.00. On average, they predict the company's stock price to reach $70.22 in the next year. This suggests a possible upside of 50.5% from the stock's current price.
View analysts price targets for NTRA or view top-rated stocks among Wall Street analysts.
How have NTRA shares performed in 2023?: Natera's stock was trading at $40.17 at the start of the year. Since then, NTRA stock has increased by 16.2% and is now trading at $46.66.
View the best growth stocks for 2023 here.
When is Natera's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our NTRA earnings forecast.
How were Natera's earnings last quarter?: Natera, Inc. (NASDAQ:NTRA) released its quarterly earnings results on Thursday, August, 3rd. The medical research company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($1.09) by $0.12. The medical research company had revenue of $261.40 million for the quarter, compared to analysts' expectations of $241.67 million. Natera had a negative net margin of 54.97% and a negative trailing twelve-month return on equity of 88.47%. The business's revenue was up 31.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.50) earnings per share.
What ETFs hold Natera's stock?: ETFs with the largest weight of Natera (NASDAQ:NTRA) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Alger 35 ETF (ATFV), Alger Mid Cap 40 ETF (FRTY), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), ROBO Global Healthcare Technology and Innovation ETF (HTEC), First Trust Health Care AlphaDEX Fund (FXH), Principal Healthcare Innovators ETF (BTEC) and VanEck Biotech ETF (BBH).
What guidance has Natera issued on next quarter's earnings?: Natera issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.01 billion-$1.03 billion, compared to the consensus revenue estimate of $1.01 billion.
What is Steve Chapman's approval rating as Natera's CEO?: 158 employees have rated Natera Chief Executive Officer Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Natera own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN).
When did Natera IPO?: (NTRA) raised $101 million in an initial public offering (IPO) on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.
What is Natera's stock symbol?: Natera trades on the NASDAQ under the ticker symbol "NTRA."
Who are Natera's major shareholders?: Natera's stock is owned by many different retail and institutional investors. Top institutional shareholders include State Street Corp (2.71%), Alliancebernstein L.P. (2.68%), Kynam Capital Management LP (2.53%), Geode Capital Management LLC (1.44%), Principal Financial Group Inc. (1.29%) and Marshall Wace LLP (1.23%). Insiders that own company stock include Daniel Rabinowitz, Gail Boxer Marcus, Herm Rosenman, James Healy, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Patrick J Donovan, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Steven Leonard Chapman, Todd C Cozzens and Todd C Cozzens.
View institutional ownership trends.
How do I buy shares of Natera?: Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Natera's stock price today?: One share of NTRA stock can currently be purchased for approximately $46.66.
How much money does Natera make?: Natera (NASDAQ:NTRA) has a market capitalization of $5.35 billion and generates $931.05 million in revenue each year. The medical research company earns $-547,800,000.00 in net income (profit) each year or ($4.82) on an earnings per share basis.
How many employees does Natera have?: The company employs 3,018 workers across the globe.
How can I contact Natera?: Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The official website for the company is www.natera.com. The medical research company can be reached via phone at (650) 249-9090 or via email at mbrophy@natera.com.

This page (NASDAQ:NTRA) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial